Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | CCR1 | P32246 | 3/20 | 0.54 |
| ▸ | CCR5 | P51681 | 3/20 | 0.54 |
| ▸ | CCR8 | P51685 | 3/20 | 0.54 |
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GMNN | O75496 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28958656 | 0.98 | LMNA (0.52) | LMNACCR1CCR5CCR8MMP2 | |
| SCHEMBL2809624 | 0.74 | KDM4E (0.45) | LMNACCR1CCR5CCR8MMP2 | |
| SCHEMBL23218293 | 0.73 | KDM4E (0.58) | LMNACCR1CCR5CCR8MMP2 | |
| SCHEMBL2852558 | 0.73 | CYP3A4 (0.47) | LMNATSHRCYP3A4KDM4EMAPT | |
| SCHEMBL3943646 | 0.73 | MAPT (0.58) | LMNATSHRCYP3A4KDM4ETP53 | |
| SCHEMBL9980542 | 0.73 | EGFR (0.37) | ALDH1A1 | |
| Phenanthroline SCHEMBL29367277 | 0.72 | CCR1 (1.00) | LMNACCR1CCR5CCR8MMP2 | |
| Phenanthroline SCHEMBL29354015 | 0.72 | CCR1 (1.00) | LMNACCR1CCR5CCR8MMP2 | |
| Phenanthroline SCHEMBL8845760 | 0.72 | CCR1 (1.00) | LMNACCR1CCR5CCR8MMP2 | |
| Phenanthroline SCHEMBL8312 | 0.72 | CCR1 (1.00) | LMNACCR1CCR5CCR8MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 847 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034237-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-02-05 | — | — | US | claimed |
| US-20260034238-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-02-05 | — | — | US | claimed |
| EP-4648800-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | Genmab A/S (DK) | 2025-11-19 | — | — | EP | claimed |
| EP-4648801-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | Genmab A/S (DK) | 2025-11-19 | — | — | EP | claimed |
| EP-4608451-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | Genmab A/S (DK) | 2025-09-03 | — | — | EP | claimed |
| US-20250115680-A1 | PTK7 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-04-10 | — | — | US | claimed |
| WO-2024151890-A9 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-08-22 | — | — | WO | claimed |
| WO-2024149345-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-07-18 | — | — | WO | claimed |
| WO-2024151890-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-07-18 | — | — | WO | claimed |
| EP-4366777-A2 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-05-15 | — | — | EP | claimed |
| EP-1296644-A2 | SYSTEMS AND METHODS FOR TREATING A MUCOSAL SURFACE | 3M Innovative Properties Company (US) | 2003-04-02 | — | — | EP | claimed |
| US-20030045543-A1 | Systems and methods for treating a mucosal surface | 3M INNOVATIVE PROPERTIES COMPANY | 2003-03-06 | — | — | US | claimed |
| WO-2002102377-A1 | IMMUNE RESPONSE MODIFIERS FOR THE TREATMENT OF PERIODONTAL DISEASE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-12-27 | — | — | WO | claimed |
| US-20020058674-A1 | Systems and methods for treating a mucosal surface | 3M INNOVATIVE PROPERTIES COMPANY | 2002-05-16 | — | — | US | claimed |
| US-20020016332-A1 | Imidazo-, oxazolo- and thiazolo- pyridineamines and naphthyridineamines which may be fused to cycloalkyl or benzene rings as immune reponse modifiers | 3M INNOVATIVE PROPERTIES COMPANY | 2002-02-07 | — | — | US | claimed |
| WO-2001097795-A2 | SYSTEMS AND METHODS FOR TREATING A MUCOSAL SURFACE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2001-12-27 | — | — | WO | claimed |
| WO-2001074343-A2 | METHOD FOR THE TREATMENT OF DERMAL LESIONS CAUSED BY ENVENOMATION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2001-10-11 | — | — | WO | claimed |
| US-4256819-A | MEROCYANINES | EASTMAN KODAK COMPANY (US) | 1981-03-17 | — | — | US | claimed |
| US-4254198-A | Electrophotosensitive materials for migration imaging processes | EASTMAN KODAK COMPANY (US) | 1981-03-03 | — | — | US | claimed |
| US-4166740-A | CYANINE DYES | EASTMAN KODAK COMPANY (US) | 1979-09-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034237-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | CSGALNACT1, SLC43A1, OSTC | LMNA 1233/4885CCR1 115/4885CCR5 1573/4885 |
| US-20020058674-A1 | Systems and methods for treating a mucosal surface | INMT, ICOS, HRH2 | LMNA 3662/4885CCR1 641/4885CCR5 1009/4885 |
| US-20030045543-A1 | Systems and methods for treating a mucosal surface | INMT, ICOS, HRH2 | LMNA 3662/4885CCR1 641/4885CCR5 1009/4885 |
| US-20250115680-A1 | PTK7 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | PTK2B, PTK2, LTK | LMNA 4448/4885CCR1 1607/4885CCR5 1523/4885 |
| US-20020016332-A1 | Imidazo-, oxazolo- and thiazolo- pyridineamines and naphthyridineamines which may be fused to cycloalkyl or benzene rings as immune reponse modifiers | STING1, HRH4, ICOS | LMNA 2041/4885CCR1 345/4885CCR5 224/4885 |
| US-20260034238-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | MGAT3, GALE, GPI | LMNA 775/4885CCR1 821/4885CCR5 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.